NCT01542307

Brief Summary

This is a pilot study investigating the therapeutic potential of breathing 100% oxygen in acute migraine headache.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jul 2012

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 21, 2012

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 2, 2012

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2012

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

March 27, 2017

Completed
Last Updated

March 27, 2017

Status Verified

February 1, 2017

Enrollment Period

3.2 years

First QC Date

February 21, 2012

Results QC Date

October 16, 2016

Last Update Submit

February 3, 2017

Conditions

Keywords

migraineoxygen therapy

Outcome Measures

Primary Outcomes (1)

  • Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS)

    The mean change in VAS pain scores from 0 minutes to 30 minutes was selected as the primary outcome measure. The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.

    From baseline (0 minutes) to 30 mins

Secondary Outcomes (6)

  • Change in Pain Score From 0-15 Minutes on the Visual Analogue Scale (VAS)

    Baseline (0 minutes) to 15 minutes

  • Change in Pain Score From 0-60 Minutes on the Visual Analogue Scale (VAS)

    Baseline (0 minutes) to 60 minutes

  • Final Pain Severity Score 0-1 on the Visual Analogue Scale (VAS)

    60 minutes

  • Final Pain Score 0-1 or Score Improved 3 or More Points on the Visual Analogue Scale (VAS)

    60 minutes

  • Final Visual Symptom Score 0-1 on the Visual Analog Scale (VAS)

    60 minutes

  • +1 more secondary outcomes

Other Outcomes (1)

  • Post-gas Therapy Medication Use

    60 minutes

Study Arms (2)

Oxygen

EXPERIMENTAL

Oxygen is inhaled for 30 minutes during migraine attack

Biological: Oxygen

Room Air

PLACEBO COMPARATOR

Medical air inhaled for 30 minutes during migraine attack

Biological: Room air

Interventions

OxygenBIOLOGICAL

Oxygen is inhaled for 30 minutes during migraine attack

Oxygen
Room airBIOLOGICAL

Placebo

Room Air

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult subjects with frequent migraine (at least 1 attack per month)

You may not qualify if:

  • Secondary (non-migraine) headache
  • Chronic obstructive pulmonary disease
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Publications (1)

  • Singhal AB, Maas MB, Goldstein JN, Mills BB, Chen DW, Ayata C, Kacmarek RM, Topcuoglu MA. High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. Cephalalgia. 2017 Jul;37(8):730-736. doi: 10.1177/0333102416651453. Epub 2016 May 20.

MeSH Terms

Conditions

Migraine Disorders

Interventions

Oxygen

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

ChalcogensElementsInorganic ChemicalsGases

Results Point of Contact

Title
Aneesh Singhal, MD
Organization
Massachusetts General Hospital

Study Officials

  • Aneesh B Singhal, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Neurology

Study Record Dates

First Submitted

February 21, 2012

First Posted

March 2, 2012

Study Start

July 1, 2012

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

March 27, 2017

Results First Posted

March 27, 2017

Record last verified: 2017-02

Locations